Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Squamous Cell Carcinoma Clinical Trials

A listing of Squamous Cell Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (611) clinical trials

This trial is an open-label, single arm phase II study assessing the tolerability and anti-tumour activity of afatinib when given in combination with a fixed dose of pembrolizumab in patients with squamous NSCLC, who progressed during or after first line platinum-based standard therapy and had no prior treatment with an ...

Phase

People with Head and Neck Squamous Cell Carcinoma (HNSCC) are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

All enrolled patients will receive CDX-3379 and cetuximab. All patients in the study will be closely monitored to determine if there is a response to the treatment and for any side effects that may occur.

Phase

People with head and neck squamous cell carcinoma may be eligible to participate in a research study being conducted by Northwell Health.  

People with head and neck squamous cell carcinoma may be eligible to participate in a research study being conducted by Montefiore Medical Center.  

Phase N/A

People with cervical cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.  

Phase N/A

People with head and neck squamous cell carcinoma are asked to participate in a research study being conducted by Northwell Health.  

Phase N/A

People with head and neck squamous cell carcinoma may participate in a research study being conducted by Montefiore Medical Center.  

Phase N/A

This is a clinical trial aimed to determine the best tolerated dosage of Cetuximab into arteries for the treatement of un-resectable recurrent head and neck cancer. Cetuximab belongs in a class of drugs called epidermal growth factor receptor (EGFR) inhibitors. A high percentage of head and neck cancers over-express EGFR. ...

Phase